研究人员提出一项前瞻性、纵向、观察性研究，通过使用人工智能（AI）分析每位个体随时间变化的血浆分子模式，以识别用于早期检测非传染性疾病（NCDs）的关键测量指标，从而改善健康评估。该研究将制定个人化参考范围及筛查方法，为基于人群的早期检测奠定基础。
适应症：CVD、Type 2 Diabetes、COPD、Cancer、Hypertension
入组条件
纳入标准
- Signed informed consent form (ICF) of the study.
- Male or female participants.
- Age at Visit 1: 40 years - 70 years.
- For Low-risk Arm: Has low risk to contract an NCD in the upcoming years, according to the following criteria: a) Non-hypertensive person according to criteria of the relevant national guideline, who never received antihypertensive medication; b) Total cholesterol: \< 5.2 mmol/L (\<200 mg/dL) with no history of lipid-lowering (e.g., statin) treatment; c) Non smoker or with no significant smoking history (\<5 pack-years); For High-risk Arm: Has high risk to contract an NCD in the upcoming years, confirmed by the presence of at least 2 out of the following 3 criteria (a, b, c): a) Medically controlled hypertension: participants with diagnosed hypertension receiving antihypertensive medication ; b) Medically controlled dyslipidemia or hypercholesterolemia: participants with diagnosed dyslipidemia or hypercholesterolemia receiving lipid-lowering medication; c) Significant smoking history (tobacco exposure of \>20 pack-years) and/or 1st degree family member with history of lung cancer.
- BMI: 18.5 - 35.0 kg/m\^2.
- Willingness to fill in the study questionnaire.
- Willingness to participate in future visits and medical investigations as defined per protocol.
- Willingness to be followed-up on disease outcome through data linkage to the participant's health-related records.
- History of HIV, HBV, HCV or HEV infection at Visit 1.
- Vulnerable participants.
- Foreseeable lack of compliance.
排除标准
- Pregnancy at Visit 1 (self-reported, no test required).
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。